New Synthetic Biomolecule Shows Promise in Degrading Disease-Related Proteins
Novel synthetic biomolecule degrades disease-related proteins
Image: Phys.org
Researchers at Northwestern Medicine have created a synthetic biomolecular condensate that can effectively degrade disease-causing proteins, particularly targeting the KRAS oncogenic protein. This advancement may lead to new therapeutic strategies for various diseases, as detailed in a study published in Nature Communications.
- 01The synthetic biomolecular condensate targets the KRAS G12V mutation, selectively degrading it without affecting normal protein functions.
- 02The study was led by Shana Kelley, a prominent figure in biomedical engineering and chemistry, and published in Nature Communications.
- 03The new biomolecular tool incorporates a proteasome-targeting motif, enhancing antibody delivery and preserving their activity.
- 04The approach has shown potential in suppressing tumor growth in mouse models with KRAS mutations.
- 05Future research will explore how biomolecular condensates interact with cells and their potential as programmable biomaterials.
Advertisement
In-Article Ad
Scientists at Northwestern Medicine have developed a novel synthetic biomolecular condensate capable of degrading intracellular disease-related proteins, particularly the KRAS oncogenic protein, as reported in a study in *Nature Communications*. This innovative approach utilizes the cell's own degradation machinery to target disease-causing proteins, overcoming challenges posed by variations in protein structure. The condensate incorporates a proteasome-targeting motif, which improves the delivery and effectiveness of antibodies against the KRAS G12V mutation while leaving normal proteins unaffected. Lead author Yi Li noted that the technology not only degrades the targeted mutation but also suppresses tumor growth in relevant mouse models. The researchers believe this biomolecular condensate could serve as a versatile tool for targeting various intracellular proteins, with plans to further investigate how these condensates interact with cells and their potential applications in therapeutic settings. This research may pave the way for new treatment modalities across a spectrum of diseases.
Advertisement
In-Article Ad
The development of this synthetic biomolecular condensate could lead to new cancer treatments, particularly for tumors with specific mutations like KRAS G12V.
Advertisement
In-Article Ad
Reader Poll
How do you feel about the potential of synthetic biomolecules in treating diseases?
Connecting to poll...
More about Northwestern Medicine
Read the original article
Visit the source for the complete story.